UBM buys medical publisher MediMedia in £188m deal
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Lord Hollick's United Business Media yesterday announced the acquisition of a medical publisher for €283m (£188m), the company's biggest deal since selling out of consumer media in 2000.
Lord Hollick's United Business Media yesterday announced the acquisition of a medical publisher for €283m (£188m), the company's biggest deal since selling out of consumer media in 2000.
The cash purchase of MediMedia, which is focused on Europe and Asia, significantly boosts the proportion of group operations in the health care area, which had so far concentrated on the US and UK. The deal increases the size of the health care division from 17 to 23 per cent of group sales - about the same as UBM's technology publishing business.
Aside from business-to-business publishing, UBM also has a division that distributes press releases and it owns NOP market research. In February, the company, which is debt-free, said it had £500m of firepower to spend on acquisitions. Last year, UBM spent £130m on buying businesses, including the Builder Group magazines for the construction industry.
MediMedia has drug information businesses in Europe and Asia, and trade press, patient education and pharmaceutical marketing businesses in Germany, Benelux and Asia-Pacific.
Last year, MediMedia's turnover was €105.8m, with operating profits of €24.4m. UBM said the acquisition would be earnings neutral in 2004 and predicted it would increase earnings more than 5 per cent in 2005.
Stephen Warshaw, who has been responsible for MediMedia's European operations, would be appointed chief executive of the acquired businesses after completion. The deal requires the approval of a workers council.
Lord Hollick, the chief executive of UBM, said: "This proposed acquisition is an excellent fit with our strategy of building our core franchisesand extending our geographical coverage in key markets on attractive financial terms."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments